{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:15:15Z","timestamp":1793042115845,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01 HX003062"],"award-info":[{"award-number":["I01 HX003062"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.gastro.2025.08.021","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:28:21Z","timestamp":1763152101000},"page":"606-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening"],"prefix":"10.1053","volume":"170","author":[{"given":"Nicole J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Vutien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret","family":"Mecham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen","family":"Borgerding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayta","family":"Swarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranusha","family":"Atuluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey","family":"Barnard Giustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mezzacappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang","family":"VoPham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey L.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziding","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Beste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar H.","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.08.021_bib1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: Global Burden of Disease Study","volume":"82","author":"Tan","year":"2025","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2025.08.021_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.08.021_bib4","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.gastro.2025.08.021_bib5","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"8","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.08.021_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1053\/j.gastro.2025.08.021_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis","volume":"18","author":"Best","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib9","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/jcm12030949","article-title":"The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"12","author":"Guan","year":"2023","journal-title":"J Clin Med"},{"key":"10.1053\/j.gastro.2025.08.021_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.32185","article-title":"GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis","volume":"75","author":"Singal","year":"2022","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.08.021_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD Score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score","volume":"28","author":"Yang","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.gastro.2025.08.021_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/HEP.0000000000000953","article-title":"HES V2.0 outperforms GALAD for detection of HCC: a phase 3 biomarker study in the United States","volume":"81","author":"El-Serag","year":"2025","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.08.021_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cgh.2021.08.010","article-title":"Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma","volume":"20","author":"Chalasani","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib14","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1002\/hep4.2045","article-title":"Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: results of a network meta-analysis","volume":"6","author":"Singal","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2025.08.021_bib15","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/hep4.1918","article-title":"A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma","volume":"6","author":"Lin","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2025.08.021_bib16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.cgh.2013.09.053","article-title":"Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis","volume":"12","author":"Gopal","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2009.04.005","article-title":"Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma","volume":"137","author":"Marrero","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.08.021_bib18","first-page":"453","article-title":"HCC with low- and normal-serum alpha-fetoprotein levels","volume":"15","author":"Carr","year":"2018","journal-title":"Clin Pract (Lond)"},{"key":"10.1053\/j.gastro.2025.08.021_bib19","article-title":"NAFLD and MAFLD as emerging causes of HCC: a populational study","volume":"3","author":"Myers","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1053\/j.gastro.2025.08.021_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/liv.12516","article-title":"Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment","volume":"35","author":"Kim","year":"2015","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2025.08.021_bib21","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/jgh.12612","article-title":"Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B","volume":"29","author":"Shim","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0168-8278(00)00053-2","article-title":"Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status","volume":"34","author":"Trevisani","year":"2001","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib23","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1053\/j.gastro.2019.12.030","article-title":"Recent decline in hepatocellular carcinoma rates in the United States","volume":"158","author":"Shiels","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.08.021_bib24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.14309\/ajg.0000000000002561","article-title":"Racial disparities in liver disease mortality trends among black and white populations in the United States, 1999\u20132020: an analysis of CDC WONDER Database","volume":"119","author":"Wang","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.08.021_bib27","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/S2468-2667(20)30062-1","article-title":"Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019\u201340: a modelling study","volume":"5","author":"Julien","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1053\/j.gastro.2025.08.021_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6412","article-title":"Trends in characteristics, mortality, and other outcomes of patients with newly diagnosed cirrhosis","volume":"2","author":"Orman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.gastro.2025.08.021_bib29","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.gastro.2015.07.056","article-title":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001\u20132013","volume":"149","author":"Beste","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.08.021_bib30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib31","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/apt.16092","article-title":"Fibroscan liver stiffness after anti-viral treatment for hepatitis C is independently associated with adverse outcomes","volume":"52","author":"Vutien","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.08.021_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/apt.17802","article-title":"Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication","volume":"59","author":"Vutien","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.08.021_bib33","unstructured":"American Cancer Society. Liver Cancer Stages. Available at: https:\/\/www.cancer.org\/cancer\/types\/liver-cancer\/detection-diagnosis-staging\/staging.html. Last Revised February 11, 2025."},{"key":"10.1053\/j.gastro.2025.08.021_bib34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.14309\/ajg.0000000000001615","article-title":"The COVID-19 pandemic highlights opportunities to improve hepatocellular carcinoma screening and diagnosis in a national health system","volume":"117","author":"Kim","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.08.021_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1053\/j.gastro.2025.08.021_bib36","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.14309\/ajg.0000000000001906","article-title":"Combining FIB-4 and liver stiffness into the FIB-5, a single model that accurately predicts complications of portal hypertension","volume":"117","author":"Vutien","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.08.021_bib37","series-title":"Congress.Gov. Department of Veterans Affairs FY2023 Appropriations","year":"2023"},{"key":"10.1053\/j.gastro.2025.08.021_bib38","series-title":"Diagnostic Sensitivity and Specificity for Clinical Laboratory Testing","year":"2022"},{"key":"10.1053\/j.gastro.2025.08.021_bib39","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cgh.2021.08.011","article-title":"Decreasing trend of serum alpha-fetoprotein level in hepatocellular carcinoma","volume":"20","author":"Vipani","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.08.021_bib40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2025.08.021_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.14309\/ajg.0000000000001000","article-title":"Rates and predictors of undergoing different hepatocellular carcinoma screening tests in patients with cirrhosis","volume":"116","author":"Kim","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.08.021_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284914","article-title":"The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada","volume":"18","author":"Chu","year":"2023","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2025.08.021_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/liv.15143","article-title":"Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: a population-based cohort study","volume":"42","author":"Innes","year":"2022","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2025.08.021_bib44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cgh.2023.08.016","article-title":"Incidence of etiology-specific hepatocellular carcinoma: diverging trends and significant heterogeneity by race and ethnicity","volume":"22","author":"Pinheiro","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525059062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525059062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:25:26Z","timestamp":1780201526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508525059062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0016508525059062"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.08.021","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}